Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity

Publisher： Karger

E-ISSN： 1421-9794|55|6|391-398

ISSN： 0009-3157

Source： Chemotherapy, Vol.55, Iss.6, 2009-11, pp. : 391-398

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

By  

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 122-126

Karger

Access to resources Recommend Favorite

Topotecan in Platinum-Resistant Epithelial Ovarian Cancer

By  

Chemotherapy, Vol. 51, Iss. 6, 2005-11 ,pp. : 347-351

Karger

Access to resources Recommend Favorite

High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 108-111

Karger

Access to resources Recommend Favorite

Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer

By  

Chemotherapy, Vol. 56, Iss. 1, 2010-02 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors

By  

Chemotherapy, Vol. 55, Iss. 6, 2009-12 ,pp. : 441-445

Karger

Access to resources Recommend Favorite